NCT05392686 2022-05-26
PD1 and PARP for Maintenance Therapy in NSLLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Clinical Trials
1 trialsParkinson Disease 4, Autosomal Dominant Lewy Body × Poly(ADP-ribose) Polymerase Inhibitors × Clear all